New CRISPR-Based Test Detects Pathogens at Ultra-Low Concentrations

A team of researchers led by Rashid Bashir from the University of Illinois has developed a novel CRISPR-based diagnostic test capable of detecting multi-drug-resistant bacteria and other pathogens at extremely low concentrations. The research, published in Proceedings of the National Academy of Sciences, introduces a technique that bypasses the need for nucleic acid amplification, traditionally required in pathogen detection.

The new technology, dubbed CRISPR-Cascade, combines two CRISPR/Cas units to create a positive feedback loop, resulting in a high signal-to-noise ratio. This innovative approach allows for the detection of pathogen genetic material in blood at concentrations significantly lower than current single CRISPR-based techniques.

In testing, the CRISPR-Cascade system demonstrated remarkable sensitivity, detecting multi-drug-resistant Staphylococcus aureus DNA at concentrations orders of magnitude lower than existing single Cas tests. Furthermore, the technology proved capable of providing simple "yes/no" results for the presence of specific pathogens in samples containing multiple common bloodstream pathogens.

The researchers emphasize the potential impact of this technology on disease management, particularly in cases of bloodstream infections where rapid detection is crucial. "We introduce an amplification-free CRISPR-Cascade assay that detects pathogenic DNA at attomolar sensitivity within minutes, using a positive feedback loop to enhance signal amplification," the team stated.

This advancement offers a versatile and scalable platform for highly sensitive, specific, and multiplexed diagnostics. By simplifying and accelerating pathogen detection, the CRISPR-Cascade system paves the way for next-generation point-of-care tools suitable for diverse clinical settings, including resource-limited environments.